Problem
The cost of drug development and care delivery are not sustainable.
Strategy
We target early-stage companies.
Focused
We focus on companies disrupting clinical development, cell therapeutics, and patient engagement.
Early
We intend to invest early in promising opportunities that align with our investment thesis, thus managing valuation.